Comment on FR Doc # 2012-30531

I agree with the DEA and FDA assessment that Lorcaserin should be a schedule IV substance. I would like to press upon this agency that the substance review period has already spanned many months and encourage you to expedite the comment review period and final scheduling of this drug. The obesity epidemic of the United States and the rest of the world is only getting larger and Lorcaserin with the rare combination of being safe and effective will bring a much needed new tool to fight this. Thank you for allowing the public to comment.